Risk of Acute Kidney Injury with Sodium-Glucose Cotransporter-2 Inhibitors in Elderly and Very Elderly Adults Compared to the General Adult Population
by Kenina E. Silvera, 2024 PharmD Candidate, Michael W. Nagy, PharmD, BCACP
Question: In the general adult population, elderly adults, and very elderly adults, what is the risk of acute kidney injury (AKI) with sodium-glucose cotransporter-2 (SGLT2) inhibitors versus placebo?
"Sodium-glucose cotransporter-2 (SGLT2) inhibitors are used to treat type 2 diabetes mellitus (T2DM) by inhibiting there absorption of filtered glucose in the proximal convoluted tubules of the kidney, promoting urinary excretionof glucose. The five SGLT2 inhibitors approved by the FDA are: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and bexaglifloxin. Some of these agents have additionally gained approval for the use in other disease states, including heart failure and chronic kidney disease (CKD)."
Keywords: Sodium-Glucose Transporter 2 Inhibitors, Canagliflozin, Empagliflozin, Diabetes Mellitus, Type 2, Dapagliflozin, Ertugliflozin, Aldosterone, Creatinine, Renin, Diuretics, Incidence, Standard of Care, Renal Dialysis, Kidney, Renal Insufficiency, Acute Kidney Injury, Aging, Heart Failure, Diuresis, Hospitalizations
Download PDF
2023 November/December Table of Contents
Question: In the general adult population, elderly adults, and very elderly adults, what is the risk of acute kidney injury (AKI) with sodium-glucose cotransporter-2 (SGLT2) inhibitors versus placebo?
"Sodium-glucose cotransporter-2 (SGLT2) inhibitors are used to treat type 2 diabetes mellitus (T2DM) by inhibiting there absorption of filtered glucose in the proximal convoluted tubules of the kidney, promoting urinary excretionof glucose. The five SGLT2 inhibitors approved by the FDA are: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and bexaglifloxin. Some of these agents have additionally gained approval for the use in other disease states, including heart failure and chronic kidney disease (CKD)."
Keywords: Sodium-Glucose Transporter 2 Inhibitors, Canagliflozin, Empagliflozin, Diabetes Mellitus, Type 2, Dapagliflozin, Ertugliflozin, Aldosterone, Creatinine, Renin, Diuretics, Incidence, Standard of Care, Renal Dialysis, Kidney, Renal Insufficiency, Acute Kidney Injury, Aging, Heart Failure, Diuresis, Hospitalizations
Download PDF
2023 November/December Table of Contents